ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2020

Abstract Number: 0430

Outcomes of Coronavirus Disease 2019 Infection Among Patients Living with Rheumatic Diseases: A Matched Cohort Study from a US Multi-Center Research Network

Kristin D'Silva1, April Jorge1, Na Lu2, Yuqing Zhang3, Zachary Wallace4 and Hyon Choi5, 1Massachusetts General Hospital, Boston, MA, 2Arthritis Research Canada, Vancouver, BC, Canada, 3Massachusetts General Hospital, Quincy, MA, 4Massachusetts General Hospital, Newton, MA, 5Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2020

Keywords: autoimmune diseases, COVID-19, Infection

Session Information

Date: Friday, November 6, 2020

Title: Plenary Session I (0429–0433)

Session Type: Plenary Session

Session Time: 11:30AM-1:00PM

Background/Purpose: Whether patients living with systemic autoimmune rheumatic diseases (SARDs) suffer from more severe complications of Coronavirus Disease 2019 (COVID-19) infection remains unknown.

Methods: We conducted a matched cohort study to examine COVID-19 infection outcomes of patients with SARDs using the TriNETX Research Network, which contains real-time electronic health record data from >52 million patients across 35 healthcare organizations. COVID-19 infections were identified by International Classification of Diseases 10th Revision (ICD-10) codes or positive COVID-19 testing by polymerase chain reaction between January 20, 2020, and June 1, 2020. Patients with SARDs (including rheumatoid arthritis [RA], systemic lupus erythematosus [SLE], Sjogren’s syndrome, systemic sclerosis [SSc], idiopathic inflammatory myositis [IIM], mixed or undifferentiated connective tissue disease, systemic vasculitis, psoriatic arthritis [PsA], and ankylosing spondylitis [AS]) were identified by two ICD-10 codes for rheumatic disease greater than two months apart. For the comparison cohort, we matched one individual without SARDs based on age, sex, and race/ethnicity. Baseline characteristics were assessed in the 1 year prior to COVID-19 infection, and outcomes were assessed between 2 weeks and 3 months after COVID-19 infection. We calculated the risk difference and risk ratio (RR) for the association of SARD with each outcome.

Results: There were 716 patients with COVID-19 infection and SARD and 716 age-sex-race-matched comparators with COVID-19 infection but without SARD. After matching, the average age was 57 years, 79% were female, 54% were white, and 34% were Black or African American (Table 1). Patients with SARDs had higher rates of comorbidities than comparators, including hypertension, asthma, chronic kidney disease, and heart failure. Among patients with SARDs, the distribution of rheumatic disease was: 325 (45%) RA, 128 (18%) SLE, 71 (10%) Sjogren’s syndrome, 25 (3%) SSc, 20 (3%) IIM, 34 (5%) mixed or undifferentiated connective tissue disease, 61 (9%) systemic vasculitis, 44 (6%) PsA, and 22 (3%) AS. Of patients with SARDs, 289 (40%) were on prednisone, 140 (20%) were on hydroxychloroquine, and 84 (12%) were on tumor necrosis factor inhibitors. Patients with SARDs had higher risk of hospitalization (RR 1.23), intensive care unit admission (RR 1.75), mechanical ventilation (RR 1.77), acute kidney injury (RR 1.83), and congestive heart failure (RR 3.06) versus comparators without SARDs (all p< 0.05, Table 2). Mortality was numerically higher in patients with SARDs than comparators, although not statistically significant.

Conclusion: Patients with SARDs who develop COVID-19 infection may have higher risks of end-organ failure (including mechanical ventilation, acute kidney injury, and heart failure) compared to matched comparators without SARDs. Further studies are needed to identify risk factors associated with severe COVID-19 infection in patients living with SARDs.


Disclosure: K. D'Silva, None; A. Jorge, None; N. Lu, None; Y. Zhang, None; Z. Wallace, Bristol-Myers Squibb, 2; H. Choi, AstraZeneca, 2, Takeda, 5, Selecta, 5, GlaxoSmithKline, 5, Horizon, 5.

To cite this abstract in AMA style:

D'Silva K, Jorge A, Lu N, Zhang Y, Wallace Z, Choi H. Outcomes of Coronavirus Disease 2019 Infection Among Patients Living with Rheumatic Diseases: A Matched Cohort Study from a US Multi-Center Research Network [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/outcomes-of-coronavirus-disease-2019-infection-among-patients-living-with-rheumatic-diseases-a-matched-cohort-study-from-a-us-multi-center-research-network/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/outcomes-of-coronavirus-disease-2019-infection-among-patients-living-with-rheumatic-diseases-a-matched-cohort-study-from-a-us-multi-center-research-network/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology